52nd week of 2012 patent applcation highlights part 53 |
Patent application number | Title | Published |
20120329820 | Pyridinoylpiperidines As 5-HT1F Agonists - The present invention relates to compounds of formula I: | 2012-12-27 |
20120329821 | PESTICIDAL COMPOSITIONS - The invention disclosed in this document is related to field of pesticides and their use in controlling pests. | 2012-12-27 |
20120329822 | 10'-FLUORINATED VINCA ALKALOIDS PROVIDE ENHANCED BIOLOGICAL ACTIVITY AGAINST MDR CANCER CELLS - A 10′-fluoro-vinca alkaloid compound or its pharmaceutically acceptable salt is disclosed, as are methods of its preparation and use. A disclosed 10′-fluoro-vinca alkaloid compound has better cytotoxic potency against leukemia and cancer cell lines, and is about 8-times more cytotoxic to a multiple drug resistant cancer cell line than is a parental 10′-unsubstituted vinca alkaloid. | 2012-12-27 |
20120329823 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 2012-12-27 |
20120329824 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 2012-12-27 |
20120329825 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 2012-12-27 |
20120329826 | SUBSTITUTED-5-AMINOPYRROLO/PYRAZOLOPYRIDINES - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by RON and/or MET. | 2012-12-27 |
20120329827 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE - The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I inhibit HIV-integrase enzyme and are useful for preventing and treating of HIV infection and AIDS. | 2012-12-27 |
20120329828 | Cocaine Analogs and Methods of Preparation and Uses Thereof - The invention provides novel cocaine analogs. The invention also provides a method of preparing cocaine analogs with control over the substituents installed at the C-1, C-2, C-3, C-4 and N-8 positions of the tropane bicyclic scaffold. The invention further provides methods of providing anesthesia, blocking reuptake of a monoamine neurotransmitter, and treating depression, by administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of the invention. | 2012-12-27 |
20120329829 | Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications - The invention provides a class of dopamine transporter inhibitors of formula (I) (DAS inhibitors), packaged pharmaceuticals comprising such inhibitors, and their uses treating, or the manufacturing medicaments for treating disease conditions, including Parkinson's disease, Hoehn and Yahr Staging of Parkinson's Disease. Unified Parkinson Disease Rating Scale (UPDRS), and Schwab and England Activities of Daily Living Scale. Related business methods such as marketing the inhibitors to healthcare providers are also provided. | 2012-12-27 |
20120329830 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B | 2012-12-27 |
20120329831 | PHARMACEUTICAL COMPOSITION OF DONEPEZIL - The present invention relates to a pharmaceutical composition of donepezil or pharmaceutically acceptable salts thereof comprising ethyl cellulose and methacrylic acid copolymer in a ratio of more than 1.3. Further, it relates to process for preparation of said composition. | 2012-12-27 |
20120329832 | Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use - This invention relates to novel coumarin derivative, formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents. | 2012-12-27 |
20120329833 | USE OF ANTAGONISTS OF THE CBI RECEPTOR FOR THE MANUFACTURE OF A COMPOSITION USEFUL FOR THE TREATMENT OF HEPATIC DISEASES - The invention relates to the use of antagonists to the CB1 receptor for the preparation of a composition for the treatment of hepatic diseases and preferably to the use of N-piperidino5 5-(4-chlorophenyl)-1-(2, 4-dichloropenyl)-4-methylpyrazole-3-carboxamide. | 2012-12-27 |
20120329834 | COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES - The present invention relates to the use of compounds of general formula (I): (I) for the preparation of medicaments that act against mitochondrial pathologies involving a deficiency in ATP production via the oxidative phosphorylation pathway, such as mitochondrial diseases. | 2012-12-27 |
20120329835 | USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS - Compounds of the formula (1) are disclosed and are suitable for the treatment of seborrheic dermatitis. | 2012-12-27 |
20120329836 | METHODS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER - Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2α) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and/or a prodrug thereof which can be used to treat cancer. | 2012-12-27 |
20120329837 | CATHEPSIN INHIBITORS FOR TREATING MICROGLIA-MEDIATED NEURON LOSS IN THE CENTRAL NERVOUS SYSTEM - The present invention concerns methods of using Cathepsin S inhibitors and compounds of Formula I that are inhibitors of cathepsin S in treating CNS disorders, diseases, and injuries, particularly neurodegenerative conditions. The present invention is directed to pharmaceutical compositions comprising these compounds for treating CNS disorders. | 2012-12-27 |
20120329838 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS - Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided. | 2012-12-27 |
20120329839 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS - Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided. | 2012-12-27 |
20120329840 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS - Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided. | 2012-12-27 |
20120329841 | TREATING CANCER WITH DESTHIAZOLYL RITONAVIR - Treatment of cancer includes administering a compound of formula I, for example desritonavir, to a subject. In particular, treatment of breast cancer is described. | 2012-12-27 |
20120329842 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES - The present invention concerns methods and/or compositions for treatment and/or prevention of bacterial infection wherein the bacteria has at least one metallo-β-lactamase. The bacteria are provided with an inhibitor of the metallo-β-lactamase, for example in conjunction with an antibiotic that targets the bacteria. The bacteria may be a drug-resistant strain or susceptible to becoming a drug-resistant strain. In specific embodiments, the bacteria is | 2012-12-27 |
20120329843 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN - The present invention provides a method of treating a patient suffering from pain or other FAAH mediated conditions by administering a fatty acid amide inhibiting amount of a compound represented by the formula: | 2012-12-27 |
20120329844 | VALSARTAN SALTS - The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt. | 2012-12-27 |
20120329845 | PHARMACEUTICAL COMPOSITION - Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1) below, 50-95% by mass of an alcohol, and 0.1-35% by mass of water and/or an anionic surfactant. | 2012-12-27 |
20120329846 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-ALPHA PRODUCTION INHIBITOR - Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day. | 2012-12-27 |
20120329847 | PYRAZOLE MICROBIOCIDES - Compounds of formula (I) wherein R | 2012-12-27 |
20120329848 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF - The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions eases characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis). | 2012-12-27 |
20120329849 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION - This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation. | 2012-12-27 |
20120329850 | Methods for treating retinopathy with extended therapeutic effect - Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy. | 2012-12-27 |
20120329851 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders. | 2012-12-27 |
20120329852 | COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient. | 2012-12-27 |
20120329853 | MICRORNA-BASED METHOD FOR ANTI-COLORECTAL CANCER EFFECTS AND PROGNOSIS OF COLORECTAL CANCER - The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer. | 2012-12-27 |
20120329854 | Methods and Compounds for the Diagnosis and Treatment for Cancer - The present invention provides in vitro methods for detecting, grading or prognosticating cancer, in particular prostate cancer. The invention further provides isolated polynucleotides suitable for reducing or inhibiting the expression of protein kinase C beta I and/or II and/or alpha (and consequently the levels of histone H3 phosphorylated at threonine 6, histone H3 monomethylated at lysine 4, histone H3 dimethylated at lysine 4, histone H3 trimethylated at lysine 4) and further relates to pharmaceutical compositions comprising said polynucleotides for the treatment or prevention of cancer, in particular prostate cancer. | 2012-12-27 |
20120329855 | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense polynucleotides of Hepatocyte Growth Factor (HGF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HGF. | 2012-12-27 |
20120329856 | Methods And Compositions For Reducing Viral Genome Amounts In A Target Cell - Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition. | 2012-12-27 |
20120329857 | Short Hairpin RNAs for Inhibition of Gene Expression - Methods, compositions, and kits that include small hairpin RNA (shRNA) useful for inhibition of gene expression, such as viral-mediated gene expression, are described. | 2012-12-27 |
20120329858 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION - Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. | 2012-12-27 |
20120329859 | MicroRNA Fingerprints During Human Megakaryocytopoiesis - Described herein is a method of decreasing expression of MAFB in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a MAFB gene product where an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the MAFB gene product in the subject. | 2012-12-27 |
20120329860 | Uses of Beta-Nicotinamide Adenine Dinucleotide - The present invention provides methods for treating inflammation in the lungs of a subject in need of such treatment, comprising the step of administering an effective amount of a composition comprising b-nicotinamide adenine dinucleotide to the subject. Also provided is a method of increasing integrity of a vascular barrier in a subject, comprising the step of contacting one or both of human P2Y1 receptors or P2Y11 receptors in the subject with an amount of a composition comprising beta-nicotinamide adenine dinucleotide effective to activate the receptors; wherein activation thereof increases the integrity of the vascular barrier in the subject. | 2012-12-27 |
20120329861 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES - The present invention provides a method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy. Also provided are methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors. | 2012-12-27 |
20120329862 | NOVEL COMPOUND HAVING INHIBITORY EFFECT ON LIPASE - This invention provides, a novel polyphenol compound having lipase inhibitory activity derived from tealeaves, a process for the preparation of the compound, and foods and/or beverages and pharmaceutical drugs containing the compound. | 2012-12-27 |
20120329863 | ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA - The present disclosure provides compositions and methods for alleviating inflammatory-associated diseases and conditions. These methods include administering individual and/or a mixture of multiple flavans isolated from a single or multiple | 2012-12-27 |
20120329864 | SYNERGISTIC EFFECT OF TOCOTRIENOLS AND CURCUMIN - A transdermal fluid is provided wherein the main ingredient is tocotrienol, and curcumin is added to enhance the anti-cancer effects of tocotrienols. The composition is useful for the treatment or prevention of a cancer, a tumour or an inflammatory disorder, particularly breast cancer. | 2012-12-27 |
20120329865 | MOLECULES RELATED hERG ION CHANNELS AND THE USE THEREOF - Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R | 2012-12-27 |
20120329866 | THERAPEUTIC COMPOUNDS - The invention provides compounds of Formula (I): | 2012-12-27 |
20120329867 | USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR ADMINISTRATION SHORTLY AFTER AMIODARONE DISCONTINUATION - The present invention concerns the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention and/or treatment of patients with atrial fibrillation (AF) or atrial Flutter (AFL), shortly after discontinuation of a previous treatment with amiodarone. | 2012-12-27 |
20120329868 | PARACONIC ACIDS AS PIGMENTATION ACTIVATORS - The invention relates to a mixture comprising protolichesterinic acid or a salt thereof or a diastereoisomer thereof or a derivative thereof, and lichesterinic acid or a salt thereof or an enantiomer thereof or a derivative thereof, for use for stimulating pigmentation of the skin and/or of its appendages. | 2012-12-27 |
20120329869 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - The present invention relates to benzyloxyanilide derivatives having the following structural formula: | 2012-12-27 |
20120329870 | Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders - Described herein is the use of ribonucleotide reductase inhibitors in the prevention or treatment of restenosis and other vascular proliferative disorders. | 2012-12-27 |
20120329871 | ANTIMICROBIAL COMPOUNDS - A compound for use as an antimicrobial having a formula (A). | 2012-12-27 |
20120329872 | Ready-To-Eat Feed For Domestic Pets - A new finished feed for domestic pets is proposed, containing at least one guanidinoacetic acid component as the active component with regard to nutritional physiology. The new finished feed which preferably has a water content of >8% by weight, can be produced in an extremely economical manner, wherein the main component has a significantly higher stability during passage through the gastrointestinal tract and is therefore only converted into creative under physiological conditions. For this reason the guanidinoacetic acid is also utilized to a high degree by the target group which is in particular cats and dogs. | 2012-12-27 |
20120329873 | D-SERINE FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS - The present invention relates to therapeutic methods using pharmaceutical compositions comprising one or a combination of co-agonists at the N-methyl-D-aspartate receptor for the treatment of visual system disorders. | 2012-12-27 |
20120329874 | SYNERGETIC COMPOSITION COMPRISING FLAVOURING SUBSTANCES AND ORGANIC ACIDS AND USE THEREOF - The present invention relates to a composition comprising a synergetic mixture of flavourings or flavouring substances and organic acids. Moreover, the present invention relates to the use of said composition as a preservative for animal foodstuffs and additives intended preferably for monogastric animals. | 2012-12-27 |
20120329875 | Ibuprofen for Topical Administration - Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl) propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide. | 2012-12-27 |
20120329876 | METHOD AND COMPOSITION FOR STABLE AND CONTROLLED DELIVERY OF (-)-HYDROXYCITRIC ACID - The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption. | 2012-12-27 |
20120329877 | Cycloalkyl-dione Derivatives And Methods Of Their Use - The present invention is directed to compounds of formula I: | 2012-12-27 |
20120329878 | PHENOTYPING TUMOR-INFILTRATING LEUKOCYTES - The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient. | 2012-12-27 |
20120329879 | BETA-ADRENERGIC RECEPTOR AGONISTS AND USES THEREOF - Provided herein are methods for improving function in a retinal cell associated with a diabetic condition and for treating a diabetic retinopathic condition in a subject. The methods comprise contacting the retinal cell or administering to the subject a beta-adrenergic receptor agonist or R-isomer thereof such as have the chemical structural formula: | 2012-12-27 |
20120329880 | METHOD OF PREPARING OIL SUSPENSIONS OF CAROTENOID WITH LOW VISCOSITY AND HIGH FLUIDITY AND USE THEREOF - The present invention relates to a method of preparing for an oil suspension of carotenoid with low viscosity and high fluidity and use thereof. The method comprises the following steps: mixing carotenoid crystals with tetrahydrofuran, heating the mixture to reflux temperature 50˜70°C. under stirring to dissolve the crystal, filtering and condensing to obtain the concentrate; mixing the concentrate with ketone solvent, heating the mixture to reflux temperature 60-80□ to dissolve the concentrate, filtering, condensing, adding absolute alcohol, crystallizing under stirring at room temperature, filtering and drying in vacuum to obtain carotenoid crystals; mixing carotenoids crystals after granded with plant oil or grinding carotenoid crystals with plant oils and then adding plant oil, to obtain the oil suspension of carotenoid with low viscosity and high fluidity. While the content of carotenoid is 10.0˜45.0 wt. % in the oil suspension of carotenoid obtained from the present invention, the oil suspension of carotenoid has high fluidity at temperature 5˜25□, and in the meanwhile do not need any extra heating steps during applications. | 2012-12-27 |
20120329881 | Methods for disinfecting and sanitizing cosmetics and cosmetic tools - Disclosed is a disinfecting, sanitizing, and conditioning product which may be applied to cosmetics and cosmetic tools. | 2012-12-27 |
20120329882 | pH Responsive Self-Heating Hydrogels Formed By Boronate-Catechol Complexation - Biocompatible hydrogels made from cross-linked catechol-borate ester polymers are disclosed, along with methods of synthesizing and using such hydrogels. The hydrogels of the present invention are prepared by boronic acid-catechol complexation between catechol-containing macromonomers and boronic acid-containing cross-linkers. The resulting hydrogels are pH-responsive and self-healing, and can be used in a number of different biomedical applications, including in surgical implants, in surgical adhesives, and in drug delivery systems is data provides further evidence of the viability of using the disclosed hydrogels for in vivo in biomedical applications. | 2012-12-27 |
20120329883 | Polyurethane Elastomers - This disclosure relates to a linear polymer obtained by reacting a polyethylene glycol, a polypropylene glycol; a diol; and a diisocyanate, as well as a controlled release composition containing the linear polymer together with an active agent. The active agent can have a molecular weight of 200 g/mol to 20,000 g/mol. | 2012-12-27 |
20120329884 | Food Ingredients From Stevia Rebaudiana - Various ingredients and compositions are prepared from | 2012-12-27 |
20120329885 | Ultraviolet light absorbing compounds based on benzyl substituted 2-(2- hydroxyphenyl) benzotriazoles - The present invention relates to ultraviolet light absorbing compounds having the formula I and compositions containing these compounds in combination with polymers and/or carriers: | 2012-12-27 |
20120329886 | USE OF PERIOSTIN AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 2012-12-27 |
20120329887 | BIODEGRADABLE POLYORGANOSILOXANE DEMULSIFIER COMPOSITION AND METHOD FOR MAKING THE SAME - There is provided herein a demulsifying composition comprising at least one polyorganosiloxane compound having the general formula (I): | 2012-12-27 |
20120329888 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS - Method of producing a nanoparticle suspension with the steps (i) preparation of an emulsion of a disperse polar phase, where the aqueous phase comprises one or more precursor substances forming the nanoparticles, in a continuous organic phase in the presence of an emulsifier stabilizing the emulsion, (ii) conversion of the one or more precursor substances to nanoparticles in the disperse aqueous phase, (iii) breaking of the emulsion and phase separation, where the nanoparticle suspension is obtained as one phase, (iv) separation off of the nanoparticle suspension, (v) optionally isolation of the nanoparticles from the nanoparticle suspension, wherein the emulsifier is selected from compounds of the general formula (I) in which X is O, NH, Y is C(O), NH, R is a saturated or a mono- or polyunsaturated, linear or branched hydrocarbon radical having 6 to 30 carbon atoms and R | 2012-12-27 |
20120329889 | METHOD FOR MAKING A COBALT METAL FOAM CATALYST IN WHICH A COBALT CATALYST POWDER IS COATED ONTO THE SURFACE OF A METAL FOAM, THE COBALT METAL FOAM CATALYST, A THERMAL-MEDIUM- CIRCULATING HEAT-EXCHANGE REACTOR USING THE COBALT METAL FOAM CATALYST, AND A METHOD FOR PRODUCING A LIQUID FUEL BY MEANS OF A FISCHER-TROPSCH SYNTHESIS REACTION USING THE THERMAL-MEDIUM-CIRCULATING HEAT-EXCHANGE REACTOR - The present invention relates to a method of manufacturing a cobalt metal foam catalyst including a metal foam coated with cobalt catalyst powder, a cobalt metal foam catalyst manufactured by the method, a thermal medium-circulated heat exchanger type reactor using the cobalt metal foam catalyst, and a method of producing liquid fuel by Fischer-Tropsch synthesis using the reactor. An object of the present invention is to provide a catalyst, which is used to obtain high liquid fuel productivity even at a low CO conversion ratio because the reaction temperature can be kept stable by controlling reaction heat with high efficiency in Fischer-Tropsch synthesis so that the mass transfer characteristics of a catalyst layer can be improved, and a method of manufacturing the catalyst, a reactor filled with the catalyst, and a method of producing liquid fuel using the reactor. The method of manufacturing a cobalt metal foam catalyst includes the steps of: surface-pretreating a metal foam by atomic layer deposition (ALD) using trimethylaluminum ((CH | 2012-12-27 |
20120329890 | FISCHER-TROPSCH SYNTHESIS CATALYST, MANUFACTURING METHOD THEREFOR, AND HYDROCARBON MANUFACTURING METHOD - A Fischer-Tropsch synthesis catalyst containing 10 to 30% by mass, as a metal atom, of metallic cobalt and/or cobalt oxide, based on the mass of the catalyst, supported on a carrier containing silica, in which the carrier has an average pore diameter of 8 to 25 nm and the metallic cobalt and/or cobalt oxide has an average crystallite diameter of not less than the average pore diameter of the carrier and less than 35 nm. | 2012-12-27 |
20120329891 | ION EXCHANGEABLE MIXTURE AND METHOD OF PRODUCING THE SAME - An ion exchangeable mixture containing a polymeric compound consisting of an ion exchange resin, an acrylamide mixture containing at least one bisacrylamide and at least one acrylamide, and a copolymer obtained by reacting the polymeric compound with the acrylamide mixture, and a method of producing the same are provided. The ion exchangeable membrane produced by using the ion exchangeable mixture has significantly smaller electric resistance than conventional ion exchangeable membranes, and has excellent selective permeability because the ion exchangeable membrane is electrically charged. The ion exchangeable membrane can be produced under very mild production conditions, and thus can be produced very easily. Furthermore, the ion exchangeable membrane can be also formed into film during a crosslinking reaction in a solvent of water, and thus is advantageous in that the ion exchangeable membrane can be freely produced into desired sizes, shapes and forms. | 2012-12-27 |
20120329892 | FOAMS BASED ON THERMOPLASTIC POLYURETHANES - Expandable thermoplastic polyurethane comprising blowing agent, wherein the Shore hardness of the thermoplastic polyurethane is from A 44 to A 84. | 2012-12-27 |
20120329893 | HYDROCHLOROFLUOROOLEFIN BLOWING AGENT COMPOSITIONS - The invention relates to the use of a composition as an agent for blowing a projected biocomponent polyurethane foam, said composition including 1-chloro-3,3,3-trifluoropropane and/or 2-chloro-3,3,3-trifluoropropene and at least one additional compound selected from among hydrochlorofluoroolefins, hydrofluoroolefins, hydrochloroolefins, hydrofluorocarbons, hydrochlorofluorocarbons, hydrocarbons, substituted or non-substituted ethers, substituted or non-substituted alcohols, substituted or non-substituted aldehydes, substituted or non-substituted ketones and substituted or non-substituted esters. Said composition has a boiling point greater than or equal to 20° C. The invention also relates to a method for manufacturing polyurethane foam on the basis of the use above and moreover relates to specific compositions that are appropriate for implementing the invention. | 2012-12-27 |
20120329894 | POLYPROPYLENE SERIES RESIN POROUS FILM, BATTERY SEPARATOR AND BATTERY - Regarding a polypropylene series resin porous film having a polypropylene series resin as the main component, so as to exert excellent slipping ability and processability when used as a battery separator, a polypropylene series resin porous film fabricated in such a way that the coefficient of static friction against film is greater than the coefficient of static friction against SUS is proposed. | 2012-12-27 |
20120329895 | RADIATION-CURABLE WHIPPED FOAMS - The present invention relates to a process for the production of radiation-cured foams, characterized in that the radiation-cured foams are produced by 1) foaming of an aqueous composition A), 2) thermal drying of the foam produced from step 1), 3) curing of the foam by actinic radiation, the radiation-curable aqueous compositions A), the radiation-cured foams produced by the process according to the invention and the use of the radiation-cured foams for coating substrates. | 2012-12-27 |
20120329896 | VISCOELASTIC SILICON RUBBER COMPOSITIONS - This invention relates to viscoelastic silicone rubber compositions that are the products of the reaction of: (a) a silanol-terminated polyorganosiloxane base; (b) a boron-containing crosslinking agent; and (c) a siloxane bond-forming crosslinking agent. In a viscoelastic silicone rubber composition of the invention some of the crosslinks, the siloxane crosslinks, are permanent and others of the crosslinks, the boron-containing crosslinks, are temporary. Because a fraction of its crosslinks can come apart and then reform, a viscoelastic silicone rubber composition of the invention can relax stress in response to strain and thus adapt to new shapes. The composition has sufficient permanent crosslinks, however, to establish a permanent equilibrium shape to which the composition will eventually return when not subject to any imposed stress. A viscoelastic silicone rubber composition has sufficient temporary crosslinks to give the composition a stiffness that is greater on short timescales than it is on longer timescales. | 2012-12-27 |
20120329897 | DUAL CURING COMPOSITION AND USE THEREOF - The invention relates to combined radiation- and moisture-curing compounds, which are characterized in particular by rapid curing by means of moisture. The compounds can be used as adhesives, coatings or potting materials. The use of the compounds according to the invention is particularly preferred for filling electro-optical components. | 2012-12-27 |
20120329898 | 2-OCTYL (METH)ACRYLATE ADHESIVE COMPOSITION - A pressure sensitive adhesive composition comprising a 2-octyl(meth)acrylate, (meth)acrylic acid copolymer and optional crosslinking agents is described. The adhesive composition may be derived from renewable resources and provides good peel, shear and high temperature stability. | 2012-12-27 |
20120329899 | CURABLE RESIN COMPOSITION, CURED ARTICLE THEREOF, AND OPTICAL MATERIAL - Provided is a curable resin composition which has excellent optical properties, heat resistance, transparency, low water absorbability, and mold release property in molding, and reduces the occurrence of a burr from a mold. Also provided are a cured product thereof and an optical material. The curable resin composition includes: a component (A): a soluble polyfunctional (meth)acrylic acid ester copolymer which is obtained by copolymerizing components including a monofunctional (meth)acrylic acid ester (a) having an alicyclic structure, a bifunctional (meth)acrylic acid ester (b), and 2,4-diphenyl-4-methyl-1-pentene (c), has a reactive (meth)acrylate group derived from (b) in a side chain and a structural unit derived from (c) at an end, has a Mw of 2,000 to 20,000, and is soluble in an organic solvent; a component (B): a polyfunctional (meth)acrylate; and a component (C): an initiator, in which the blending amounts (weight ratio) of the respective components are as follows: (B)/(A)=5 to 250/100, and (C)/[(B)+(A)]=0.1 to 10/100. | 2012-12-27 |
20120329900 | CATIONIC UV-CROSSLINKABLE ACRYLIC POLYMERS FOR PRESSURE SENSITIVE ADHESIVES - An ultraviolet (UV) crosslinkable acrylic pressure sensitive adhesive comprises an acrylic copolymer and a cationic photoinitiator. The acrylic copolymer comprises pendant reactive functional groups. The pressure sensitive adhesive formed from the acrylic copolymer with the pendant reactive functional groups result in high green strength and/or high temperature holding strength of the adhesive. | 2012-12-27 |
20120329901 | Biodegradable Materials for Orthopedic Devices Based on Polymer Stereocomplexes - An implantable orthopedic medical device is disclosed. The medical devices is formed from a biodegradable polymer stereocomplex comprising a biodegradable polymer including a first enantiomer and a second enantiomer, wherein the implantable medical device initially degrades at a first degradation rate and subsequently degrades at a second degradation rate that is faster than the first degradation rate. | 2012-12-27 |
20120329902 | METHODS FOR THE PREPARATION OF BIOCOMPATIBLE POLYMERS, THE POLYMERS AND THEIR USES - The subject invention relates to a method of preparing a biocompatible polymer comprising epsilon-linked L-lysine having free alpha-amino and carboxy functions. The invention further encompasses the resulting biocompatible polymer and articles made from the polymer, in particular contact and intraocular lenses. | 2012-12-27 |
20120329903 | ACID-MODIFIED URETHANE PHENOXY ACRYLATE RESIN, AND METHOD FOR PREPARING SAME - The present invention relates to an acid modified urethane phenoxy acrylate resin and a method for preparing the same. More particularly, the present invention relates to an acid modified urethane phenoxy acrylate resin in which a urethane modified acrylic group is introduced at the side chain by reacting a phenol-novolac resin with (metha)acryloyloxyalkyl isocyanate or Bis(metha)acryloyloxyalkyl isocyanate and then reacting with an acid anhydride. According to the invention, it is provided a photosensitive resin having an excellent balance by maintaining heat resistance, adhesion, chemical resistance, electric resistance and the like which are shown from a resin used in a conventional photosensitive composition and improving flexibility, toughness, extensibility and the like. | 2012-12-27 |
20120329904 | PHOTOACOUSTIC MATCHING MATERIAL AND HUMAN TISSUE SIMULATION MATERIAL - Since a medium having light propagation properties and sound propagation properties similar to those of human tissues is provided, reflection of light and an acoustic wave at a surface of a test portion is prevented, and accuracy control of a photoacoustic wave diagnostic apparatus is realized. A photoacoustic matching material is provided which includes a polyol, an inorganic oxide, and a pigment, the latter two being dispersable in the polyol, and in this photoacoustic matching material, a dispersed amount of the inorganic oxide to the polyol is in a range of 0.10 to 0.25 percent by weight, and a dispersed amount of the pigment to the polyol is in a range of 0.0001 to 0.0005 percent by weight. | 2012-12-27 |
20120329905 | High Refractive Index Lenses - An optical copolymer comprising: a constituent derived from a sulfated lens monomer of general formula I | 2012-12-27 |
20120329906 | Use of Modified Inorganic Particles as Aldehyde Scavenger and Curing Agent, in Particular in Wood Based Panels - The present invention relates to the use of at least one inorganic particle having a layered structure and being modified by cation exchange, in particular as a functional additive, as an aldehyde scavenger, in particular as a formaldehyde scavenger, as a curing agent and for improving properties of WBPs, in particular particle boards. The invention relates further to a composition comprising said particles. | 2012-12-27 |
20120329907 | REDISPERSIBLE EPOXY POWDER - A water redispersible polymer powder is produced by drying an aqueous mixture of a thermosettable epoxy resin having a glass transition temperature (T | 2012-12-27 |
20120329908 | REDISPERSIBLE EPOXY POWDER BY INTERFACIAL REACTION - A water redispersible polymer powder is produced by drying an aqueous mixture of a thermosettable epoxy resin having a glass transition temperature (T | 2012-12-27 |
20120329909 | EPOXY-BASED REDISPERSIBLE POLYMER POWDER - A polymer composition comprising at least one epoxy resin; at least one vinyl ester polymer; and at least one nonionic surfactant having a molecular weight within the range of from 1,000 to 7,000 Daltons which is different from an alkyl polyglycol ether or alkylaryl polyglycol ether having 8 to 40 ethylene oxide units. A redispersible powder comprising the polymer composition can be used in a construction chemistry product containing a hydraulic binding agent. | 2012-12-27 |
20120329910 | Thermoplastic Resin Composition and Molded Product Using the Same - Disclosed is a thermoplastic resin composition that includes: a polyester resin (A); an epoxy-modified glass fiber (C); and a hydrolysis resistant additive (D) comprising an alicyclic epoxy compound, a carbodiimide compound, or a combination thereof. | 2012-12-27 |
20120329911 | Reactive Block Copolymers as Additives for the Preparation of Silicate-Polymer Composites - A process for making a block copolymer compatibilizer comprises reacting an acrylic and/or vinyl monomer that has functional groups with one or more vinyl monomers in the presence of a free radical initiator and a stable free radical to form a reaction product that includes residual unreacted acrylic and/or vinyl monomer, and reacting one or more vinyl monomers with the reaction product to form a second block that incorporates the residual unreacted acrylic monomer. The block copolymer is used to compatibilize a clay nanocomposite material with a thermoplastic or thermoset resin. The block copolymer can be used with existing, commercially-available clays, or the block copolymer can be formed with a polar block that is miscible in a polar dispersion medium for use as a intercalate in producing a clay nanocomposite material. | 2012-12-27 |
20120329912 | FUSED FILLER AND ITS MANUFACTURING METHOD AND USE - A fused filler and method for manufacturing the same are provided. The fused filler comprises about 50 wt % to about 60 wt % SiO | 2012-12-27 |
20120329913 | CURABLE COMPOSITION COMPRISING A DI-ISOIMIDE, METHOD OF CURING, AND THE CURED COMPOSITION SO FORMED - The present invention deals with a novel curable epoxy composition comprising an aromatic di-isoimide chemical compound. The di-isoimide serves effectively as a thermally activated latent catalyst in epoxy curing, thereby increasing shelf life, and avoids premature cross-linking. Novel laminated articles and printed wiring boards, including encapsulated printed wiring boards are also disclosed. | 2012-12-27 |
20120329914 | HEAT-STABILIZED ACRYLATE ELASTOMER COMPOSITION AND PROCESS FOR ITS PRODUCTION - Polyamide-filled acrylate copolymer compositions comprising a continuous acrylate copolymer phase and a discontinuous polyamide phase are produced by a melt mixing process. When crosslinked with diamine curatives the polyamide-filled acrylate copolymer compositions exhibit enhanced resistance to heat aging compared to carbon black-reinforced acrylate copolymer compositions. | 2012-12-27 |
20120329915 | Demulsification Compositions, Systems and Methods for Demulsifying and Separating Aqueous Emulsions - The present invention provides compositions, systems and methods for demulsifying an emulsion including an aqueous phase and an organic phase by adding an effective amount of a composition comprising at least one quaternary organopolysiloxane or salt thereof to the emulsion, the composition optionally including at least one of quaternary epihalohydrin/polyamine copolymers or salts, and/or (poly)diallyldimethylammonium halides. | 2012-12-27 |
20120329916 | Keratin in Rubber Applications - A rubber composition includes an elastomer having an elongation at break (Eb) of about 50% or more according to ASTM-D 412 at 25° C., a water-insoluble keratin, and a reinforcing filler. A tire component including the composition and a method for making the composition are also disclosed. | 2012-12-27 |
20120329917 | Manufacturing Method for Resin Composition Containing Fine Paper Powder - A resin composition containing fine paper powder used in molding is obtained by using a non-intermeshing type counter-rotating twin-screw kneading extruder ( | 2012-12-27 |
20120329918 | Manufacturing Method for Resin Composition Containing Fine Paper Powder - A resin composition containing fine paper powder used in molding is obtained by using a fully-intermeshing type co-rotating twin-screw kneading extruder ( | 2012-12-27 |
20120329919 | WEATHERING-RESISTANT POLYESTER MOLDING COMPOSITIONS WITH STYRENE COPOLYMERS - The invention relates to a thermoplastic molding composition containing at least one polyester, a compound of the formula (I) | 2012-12-27 |